LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Penumbra Inc

Închisă

SectorSănătate

314.93 1.86

Rezumat

Modificarea prețului

24h

Curent

Minim

306.71

Maxim

318.64

Indicatori cheie

By Trading Economics

Venit

581K

46M

Vânzări

15M

355M

P/E

Medie Sector

73.607

76.798

Marjă de profit

12.927

Angajați

4,500

EBITDA

4M

55M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+9.29% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3B

12B

Deschiderea anterioară

313.07

Închiderea anterioară

314.93

Sentimentul știrilor

By Acuity

50%

50%

167 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Penumbra Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 dec. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec. 2025, 23:51 UTC

Câștiguri

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec. 2025, 23:39 UTC

Principalele dinamici ale pieței

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec. 2025, 21:40 UTC

Câștiguri

Nike Sales Tick Up, But China Weakness Persists

18 dec. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec. 2025, 23:37 UTC

Market Talk
Câștiguri

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec. 2025, 22:58 UTC

Achiziții, Fuziuni, Preluări

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec. 2025, 22:56 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec. 2025, 22:55 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:59 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 dec. 2025, 21:35 UTC

Câștiguri

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec. 2025, 21:31 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev Down 17% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q EPS 53c >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Apparel Rev $3.91B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Equipment Rev $550M >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q N Amer Rev $5.63B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Footwear Rev $7.66B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev $1.42B >NKE

Comparație

Modificare preț

Penumbra Inc Așteptări

Obiectiv de preț

By TipRanks

9.29% sus

Prognoză pe 12 luni

Medie 338 USD  9.29%

Maxim 388 USD

Minim 266 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPenumbra Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

13

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

288.28 / 292.9394Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

167 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat